Hologic (HOLX) officer logs small tax-related share withholding

Rhea-AI Filing Summary

Hologic executive Mark W. Horvath, President of Breast & Skeletal Health, reported a small administrative share disposition related to taxes. On February 10, 2026, 113 shares of common stock were withheld at $75.15 per share to cover tax obligations from settling restricted stock units.

After this tax-withholding transaction, Horvath directly beneficially owns 23,026 shares of Hologic common stock. This total includes 4,605 performance stock units/restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Horvath Mark W.

(Last) (First) (Middle)

250 CAMPUS DRIVE

(Street)

MARLBOROUGH MA 01752

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HOLOGIC INC [ HOLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Breast & Skeletal

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		113(1)	D	$75.15	23,026(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.

2. Includes 4,605 performance stock units/restricted stock units, the settlement of which has been deferred pursuant to the Issuer's Deferred Equity Plan.

	/s/ Mark W. Irving, attorney-in-fact for Mr. Horvath	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Hologic (HOLX) report for Mark W. Horvath?

Hologic reported that executive Mark W. Horvath had 113 shares of common stock withheld to cover tax obligations. The shares relate to the settlement of restricted stock units after service-based vesting conditions were met, rather than an open market sale or purchase.

Was the Hologic (HOLX) insider transaction a buy or sell of shares?

The filing shows a tax-withholding disposition, not a market trade. Code F indicates shares were withheld by the company to pay tax liabilities arising from restricted stock unit settlement after vesting, rather than Horvath actively buying or selling shares on the open market.

How many Hologic (HOLX) shares does Mark W. Horvath own after this filing?

Following the reported tax-withholding transaction, Mark W. Horvath directly beneficially owns 23,026 shares of Hologic common stock. This figure includes 4,605 performance and restricted stock units whose settlement has been deferred under Hologic’s Deferred Equity Plan, as described in the footnotes.

What price was used for the Hologic (HOLX) tax-withholding shares?

The 113 Hologic common shares withheld for taxes were valued at $75.15 per share. This price is the basis for calculating the tax-related share withholding tied to the settlement of previously granted restricted stock units that had satisfied their service-based vesting requirements.

What do the deferred units in the Hologic (HOLX) Form 4 represent?

The filing notes 4,605 performance stock units and restricted stock units whose settlement is deferred under Hologic’s Deferred Equity Plan. These units reflect equity awards already granted to Mark W. Horvath, with actual share delivery postponed according to the plan’s deferred settlement terms.

What is Mark W. Horvath’s role at Hologic (HOLX) in this insider filing?

Mark W. Horvath is identified as an officer of Hologic, serving as President, Breast & Skeletal. His Form 4 filing reports an administrative tax-withholding share disposition related to equity compensation, rather than a voluntary purchase or sale in the open market.